Buy (150 RUB)
|Generate QR code
Open Access
Subscription or Fee Access
Analysis of endothelial dysfunction biomarkers in patients with various cases of retinal vessel occlusion
https://doi.org/10.33667/2078-5631-2024-4-22-26
Abstract
Retinal vascular occlusion is a severe vascular condition of the retina, leading to a significant decrease in vision and blindness. Endothelial dysfunction plays a pathogenetically important role in the development of thrombosis. The aim of this study was to quantify biomarkers of endothelial dysfunction. The content of VEGF tear fluid and serum homocysteine was studied in 3 groups – in group I (patients with occlusion of the central retinal vein), group II (patients with occlusion of the central retinal artery) and control group (patients without vascular disorders). The groups were comparable in gender and age. The results showed an increased content of VEGF and homocysteine in patients with the central artery of the retina occlusion. The content of markers in patients with the central artery of the retina occlusion was significantly lower than group I, but significantly higher than the control group. The results show the involvement of the endothelium in the local thrombotic process.
About the Authors
K. I. Belskaya
City Clinical Hospital named after S. P. Botkin; Russian Medical Academy of Continuous Professional Education
Russian Federation
Russian Federation
Belskaya Ksenia I., ophthalmologist; applicant for the Dept of Ophthalmology
Moscow
L. K. Moshetova
Russian Medical Academy of Continuous Professional Education
Russian Federation
Russian Federation
Moshetova Larisa K., DM Sci (habil.), professor, academician of the Russian Academy of Sciences, head of Dept of Ophthalmology, president
Moscow
S. P. Kazakov
Main Military Clinical Hospital named after academician N. N. Burdenko Russian Defense Ministry; Federal Research and Clinical Center of specialized types of health care and medical technology of the Federal Medical and Biological Agency
Russian Federation
Russian Federation
Kazakov Sergey P., DM Sci (habil.), head of the Center for Clinical Laboratory Diagnostics, chief laboratory assistant; professor at Dept of Clinical Laboratory Diagnostics and Pathological Anatomy, president of Russian Association of Medical Laboratory Diagnostics (RAMLD)
RSCI: 5560–3931, Scopus ID –57211351588, WoS Researcher ID: C-6644–2018
Moscow
References
1. Klein R., Moss S.E., Meuer S.M., Klein B.E. The 15-year cumulative incidence of retinal vein occlusion: the Beaver Dam Eye Study. Arch Ophthalmol. 2008; 126(4):513–8.https://doi.org/10.1001/archopht.126.4.513
2. The Eye Disorders Case-Control Study Group Risk Factors for Central Retinal Vein Occlusion. Arch Ophthalmol 1996; (114): 545–54.https://doi.org/10.1001/archopht.1996.01100130537006
3. Elman M.J., Bhatt A.K., Quinlan P.M., Enger C. The risk for systemic vascular diseases and mortality in patients with central retinal vein occlusion. Ophthalmology 1990; 97(11):1543–8.https://doi.org/10.1016/s0161–6420(90)32379–5
4. Bertelsen M., Linneberg A., Christfferson N, Vorum H, Cade E, Larsen M. Mortality in patients with central retinal vein occlusion. Ophthalmology 2014; (12):637–642.https://doi.org/10.1016/j.ophtha.2013.07.025
5. Koizumi H., Ferrara D.C., Brue C., Spaide R.F. Central retinal vein occlusion case-control study. Am J Ophthalmol 2007; (144):858–63.https://doi.org/10.1016/j.ajo.2007.07.036
6. Rath EZ, Frank RN, Shin DH, Kim C. Risk factors for retinal vein occlusions. A case-control study. Ophthalmology 1992; (99):509–14.https://doi.org/10.1016/s0161–6420(92)31940–2
7. Shahsuvaryan M.L., Melkonyan A.K. Central retinal vein occlusion risk profile: a case-control study. Eur J Ophthalmol 2003; (13):445–52. https://doi.org/10.1177/112067210301300505
8. Wang Y.X., Zhang J.S., You QS, Xu.L., Jonas J.B. Ocular diseases and 10-year mortality: The Beijing Eye Study 2001.20Acta Ophthalmol. Acta Ophthalmol 2014; 92(6):424–8. https://doi.org/10.1111/aos.12370
9. Dodson, P.M., Galton, D.J., Hamilton, A.M. et al. Retinal Vein Occlusion and the Prevalence of Lipoprotein Abnormalities. Br J Ophthalmol 1982; (66): 161–164. https://doi.org/10.1136/bjo.66.3.161
10. Global report on hypertension: the race against a silent killer. Geneva: World Health Organization; 2023. Licence: CC BY-NC-SA 3.0 IGO.
11. Petrishchev N. N. Endothelial dysfunction. Causes, mechanisms, pharmacological correction. – St. Petersburg: Publishing house of St. Petersburg State Medical University, 2003. – 184 p.
12. Tultseva S. N. Endothelial regulators of fibrinolysis in patients with retinal vein thrombosis. Ophthalmological bulletin. 2009; (2):4–11.
13. FlammerJl, KonieczkaK, FlammerAJ. The primary vascular dysregulation syndrome: implications for eye diseases. EPMA J.2013; (4): 1–14.https://doi.org/10.1186/1878–5085–4–14
14. Haufschild T, Prunte C, Messerli J, Flammer JIncreased endothelin-1 plasma level in young adults with retinal vascular occlusive diseases. Klin Monbl Augenheilkd.2004; 221(5):357–359.https://doi.org/10.1055/s-2004–812813
15. Kang MH1, Balaratnasingam C, Yu PK, Morgan WH, McAllister IL, Cringle SJ, Yu DY. Morphometric characteristics of central retinal artery and vein endothelium in the normal human optic nerve head. Invest Ophthalmol Vis Sci.2011.52(3):1359–1367.https://doi.org/10.1167/iovs.10–6366
16. Lip P.L., Blann A.D., Jones A.F., Lip G.Y. Abnormalities in haemorheological factors and lipoprotein (a) in retinal vascular occlusion: implications for increased vascular risk. Eye (Lond).1998;(12):245–51.https://doi.org/10.1038/eye.1998.58
17. Rehak M., Wiedemann P. Retinal vein thrombosis: pathogenesis and management. JThromb Haemost.2010; (8):1886–1894.https://doi.org/10.1111/j.1538–7836.2010.03909.x
18. TananoIl, Nagaoka T., Sogawa K., Tani T, Omae T., Nakabayashi S., Ishibazawa A., Yoshida A. Impaired systemic vascular endothelial function in patients with branch retinal vein occlusion. Curr Eye Res.2013; (38):114–118.https://doi.org/10.3109/02713683.2012.738460
19. Wautier J.L., WautierMP.Molecular basis of erythrocyte adhesion to endothelial cells in diseases. Clin Hemorheol Microcirc.2013; (53):11–21.https://doi.org/10.3233/ch-2012–1572
20. Wu K. K., Thiagarajan P. Role of endothelium in thrombosis and hemostasis //Annu Rev Med.1996;(47): P. 315–331.https://doi.org/10.1146/annurev.med.47.1.315
21. Belenkov Yu.N., Mareev V. Yu., Ageev F. T. Endothelial dysfunction in heart failure: possibilities of therapy with ACE inhibitors Cardiology. 2001; (41):100–104.
22. Zadionchenko B. S., Adasheva T. V., Sandomirskaya A. G. Endothelial dysfunction and arterial hypertension: therapeutic options. Russian Medical Journal. 2002; (1):11–16.
23. Kramar T. V. Pathophysiological aspects of inflammatory and non-inflammatory neoangiogenesis. Crimean Journal of Experimental and Clinical Medicine.2020; (10):59–63. https://doi.org/10.37279/2224–6444–2020–10–3–59–63
24. Yoshimura T. Comprehensive analysis of inflammatory immune mediators in vitreoretinal diseases / T. Yoshimura, K. H. Sonoda, M. Sugaharaetal. PLoS ONE. – 2009. (12):8158. https://doi.org/10.1371/journal.pone.0008158
25. Bhisitkil R.B. Vascular endothelial growth factor biology: clinical implications for ocular treatment. Br J Ophthalmol. 2006;90(12):1542–1547. doi: 10.1136/bjo.2006.098426.
26. Ferrara N., Gerber H.P., Le Couter J. The biology of VEGF and its reseptors. Nat Med. 2003;9(6):669–676.https://doi.org/10.1038/nm0603–669
27. Schligemann R.O., Van Hinsberg V.W. Role of vascular permeability factor/ vascular endothelial growth factor in eye disease. Br J Ophthalmol. 1997;81(6):501–512.https://doi.org/10.1136/bjo.81.6.501
28. Campochiaro P. A., Hafiz G., Shah S. M. et al. Ranibizumab for macular edema due to retinal vein occlusions: implication of VEGF as a critical stimulator // Mol. Ther. 2008;(16):791–799.https://doi.org/10.1038/mt.2008.10
29. Branch Vein Occlusion Study Group. Argonlaser scatter photocoagulation for prevention of neovascularization and vitreous hemorrhage in branch vein occlusion. A randomized clinical trial. Arch. Ophthalmol.1996;104(1):34–41.https://doi.org/10.1001/archopht.1986.01050130044017
30. Gutman F. A., Zegarra H. Macular edema secondarу to occlusion of the retinal veins. Surv. Opthalmol. 1984;(28):462–470.https://doi.org/10.1016/0039–6257(84)90228–5
31. Shevchenko, O. P. Homocysteine and its role in clinical practice (lecture). Clinical laboratory diagnostics. 2008; (11): 25–32.
32. Bonitton-Kopp. С. Early carotid atherosclerosis in healthy middle-aged women. Kopp. Ibid. 1993;(24):1837–1843. https://doi.org/10.1161/01.str.24.12.1837
33. O. Tamai, H. Matsuoka, H. Itabe.Single LDL apheresis improves endothelium – dependent vasodilatation in hypercholesterolemic humans. Circulation. 1997;(95):76–82. https://doi.org/10.1161/01.cir.95.1.76
34. Shepherd, S. M. Cobbe, I. Ford. For the West of Scotland Coronary Prevention Study Group Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N. Engl. J. Med. 1995;(333):1301–1307.https://doi.org/10.1056/nejm199511163332001
35. Hankey G. J. Homocysteine and vascular disease. Lancet. 1999;(354):407–413. https://doi.org/10.1016/s0140–6736(98)11058–9
36. MacMahon M., Kirkpatrick C. Nutr Metab Cardiovasc. Dis. 2000;(10):195–203.
37. М. Bots, L. Launer, J. Lindemans.Homocysteine and short–term risk of myocardial infarction and stroke in the elderly. The Rotterdam Study Arch. Intern. Med. 1999;(1):138–159. https://doi.org/10.1001/archinte.159.1.38.
38. Shevchenko O. P., Olefrienko G. A. Gipergomocisteinemijaiee klinicheskoe znachenie. Laboratorija. 2002;(1):3–7.
39. Shmeleva V. M. Gipergomocisteinemijai tromboz // Tromboz, gemostazireologija. 2000;(4):26–29.
40. Arnadottir M. Homocysteine in renal disease, in Homocysteine in health and disease. Cambridge University Press, Cambridge. 2001;321–330.
41. Zagzag D., Zhong H., Scalzitti J. M., Laughner E., Simons J. W., Semenza G. L. Expression of hypoxia-inducible factor 1alpha in brain tumors: association with angiogenesis, invasion, and progression. Cancer. 2000;88(11):2606–2618.https://doi.org/10.1002/1097–0142(20000601)88:11<2606::AID-CNCR25>3.0.CO;2-W
Review
For citations:
Belskaya K.I., Moshetova L.K., Kazakov S.P. Analysis of endothelial dysfunction biomarkers in patients with various cases of retinal vessel occlusion. Medical alphabet. 2024;(4):22-26. (In Russ.) https://doi.org/10.33667/2078-5631-2024-4-22-26
Views:
84
Email this article 